Hemab Therapeutics has made a lot of progress since the last time it announced a major funding round, including taking its first drug candidate into a Phase I/II trial and identifying a second candidate that it plans to take into the clinic next year. Now, with $135m in series B venture capital that it announced on 21 February, Hemab’s operations are funded for the next three years as it works toward the goal of having five candidates for bleeding and thrombotic disorders in the clinic by 2025.
Headquartered in Copenhagen, Denmark, and Boston, Hemab launched with seed funding from Novo Seeds and technology licensed from Novo Nordisk A/S and raised a $55m series A round in November 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
